Induced pluripotent stem cells and Parkinson's disease: modelling and treatment

被引：13

作者：

Xu, Xiaoyun ^{[1
]}

Huang, Jinsha ^{[1
]}

Li, Jie ^{[1
]}

Liu, Ling ^{[1
]}

Han, Chao ^{[1
]}

Shen, Yan ^{[1
]}

Zhang, Guoxin ^{[1
]}

Jiang, Haiyang ^{[1
]}

Lin, Zhicheng ^{[2
]}

Xiong, Nian ^{[1
]}

Wang, Tao ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Dept Neurol, Union Hosp, Tongji Med Coll, 1277 Jiefang Rd, Wuhan 430022, Hubei, Peoples R China

[2] Harvard Univ, McLean Hosp, Mailman Neurosci Res Ctr, Dept Psychiat,Med Sch,Div Alcohol & Drug Abuse, Belmont, MA 02178 USA

来源：

CELL PROLIFERATION | 2016年 / 49卷 / 01期

基金：

中国国家自然科学基金;

关键词：

MIDBRAIN DOPAMINERGIC-NEURONS; IPSC-DERIVED NEURONS; PRIMATE MODEL; HIGHLY EFFICIENT; RAT MODEL; NEURAL PRECURSORS; OXIDATIVE STRESS; IN-VITRO; GENERATION; DIFFERENTIATION;

D O I：

10.1111/cpr.12229

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Many neurodegenerative disorders, such as Parkinson's disease (PD), are characterized by progressive neuronal loss in different regions of the central nervous system, contributing to brain dysfunction in the relevant patients. Stem cell therapy holds great promise for PD patients, including with foetal ventral mesencephalic cells, human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). Moreover, stem cells can be used to model neurodegenerative diseases in order to screen potential medication and explore their mechanisms of disease. However, related ethical issues, immunological rejection and lack of canonical grafting protocols limit common clinical use of stem cells. iPSCs, derived from reprogrammed somatic cells, provide new hope for cell replacement therapy. In this review, recent development in stem cell treatment for PD, using hiPSCs, as well as the potential value of hiPSCs in modelling for PD, have been summarized for application of iPSCs technology to clinical translation for PD treatment.

引用

页码：14 / 26

页数：13